Loading...
Though dermatological adverse reactions are a known complication of anti–tumor necrosis factor (TNF) agents, their incidence is not well documented. In a single-center, retrospective, observational study, researchers assessed the risk for skin complications in a cohort of 583 patients with inflammatory bowel disease (IBD) who had been treated with anti-TNF agents between 2001 and 2014. The mean follow-up duration was 38 months. Results were as follows:
Psoriasiform lesions were the most common complication; their incidence was 1.1% at 1 year, 6.8% at 5 years, and 28.9% at 10 years.
Among patients in whom anti-TNF agents were switched, psoriasis recurred in 57%.
The second most common cutaneous complication was skin infection; its incidence was…